Literature DB >> 30853207

Quantification of Serum Matrix Metallopeptide 7 Levels May Assist in the Diagnosis and Predict the Outcome for Patients with Biliary Atresia.

Jia-Feng Wu1, Yung-Ming Jeng2, Huey-Ling Chen3, Yen-Hsuan Ni3, Hong-Yuan Hsu1, Mei-Hwei Chang4.   

Abstract

OBJECTIVE: To assess the diagnostic and prognostic usefulness of the serum matrix metallopeptidase-7 (MMP-7) level for biliary atresia in infants with cholestasis after hepatoportoenterostomy. STUDY
DESIGN: We enrolled 100 infants with cholestasis (age, 43.56 ± 1.97 days; 62 males) with a direct bilirubin level of >1 mg/dL, of whom 36 (36%) were diagnosed with biliary atresisa. The MMP-7 levels in serum samples collected during the cholestasis workup and 6 months after hepatoportoenterostomy were assessed by enzyme-linked immunosorbent assay. We quantified liver fibrosis by Picro Sirius red staining of collagen in specimens from the 81 infants with cholestasis.
RESULTS: Infants with biliary atresisa had a significantly higher serum MMP-7 level than that of non-biliary atresisa infants with cholestasis of equivalent age (P < .0001). Receiver operating characteristic analysis showed that a serum MMP-7 level of >1.43 ng/mL was predictive of biliary atresisa in infants with cholestasis (diagnostic accuracy, 88%). There was a positive correlation between the serum MMP-7 level and the severity of liver fibrosis (P = .0002). Survival analysis showed that the frequency of liver transplantation was significantly higher in infants with biliary atresisa with a serum MMP-7 level of >10.30 ng/mL compared with a serum MMP-7 level of ≤10.30 ng/mL after hepatoportoenterostomy (hazard ratio, 4.22; P = .02).
CONCLUSIONS: The serum MMP-7 level, which reflects the severity of liver fibrosis and can be determined noninvasively, may facilitate the diagnosis of biliary atresisa among infants with cholestasis. Moreover, the serum MMP-7 level after hepatoportoenterostomy is associated with a need for liver transplantation in infants with biliary atresisa.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biliary atresia; cholestasis; hepatoportoenterostomy; liver fibrosis; matrix metallopeptidase 7

Mesh:

Substances:

Year:  2019        PMID: 30853207     DOI: 10.1016/j.jpeds.2018.12.006

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  14 in total

1.  Biliary Atresia as a Disease Starting In Utero: Implications for Treatment, Diagnosis, and Pathogenesis.

Authors:  Krupa R Mysore; Benjamin L Shneider; Sanjiv Harpavat
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-10       Impact factor: 2.839

Review 2.  Biliary Atresia in Children: Update on Disease Mechanism, Therapies, and Patient Outcomes.

Authors:  Swati Antala; Sarah A Taylor
Journal:  Clin Liver Dis       Date:  2022-06-25       Impact factor: 6.265

3.  Serum matrix metalloproteinase-7 levels in infants with cholestasis and biliary atresia.

Authors:  Pejman Rohani; Seyyed Bahador Mirrahimi; Haleh Bashirirad; Parisa Rahmani; Niyoosha Kamran; Hosein Alimadadi; Mahmoud Hajipour; Mohammad Hassan Sohouli
Journal:  BMC Pediatr       Date:  2022-06-18       Impact factor: 2.567

Review 4.  Recent developments in diagnostics and treatment of neonatal cholestasis.

Authors:  Amy G Feldman; Ronald J Sokol
Journal:  Semin Pediatr Surg       Date:  2020-07-23       Impact factor: 2.754

5.  Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease.

Authors:  Katharine M Irvine; Satomi Okano; Preya J Patel; Leigh U Horsfall; Suzanne Williams; Anthony Russell; Elizabeth E Powell
Journal:  Sci Rep       Date:  2021-02-03       Impact factor: 4.379

6.  A Japanese prospective multicenter study of urinary oxysterols in biliary atresia.

Authors:  Ken-Ichiro Konishi; Tatsuki Mizuochi; Hajime Takei; Ryosuke Yasuda; Hirotaka Sakaguchi; Jun Ishihara; Yugo Takaki; Masahiro Kinoshita; Naoki Hashizume; Suguru Fukahori; Hiromichi Shoji; Go Miyano; Koichiro Yoshimaru; Toshiharu Matsuura; Yukihiro Sanada; Takahisa Tainaka; Hiroo Uchida; Yumiko Kubo; Hiromu Tanaka; Hideyuki Sasaki; Tsuyoshi Murai; Jun Fujishiro; Yushiro Yamashita; Masaki Nio; Hiroshi Nittono; Akihiko Kimura
Journal:  Sci Rep       Date:  2021-03-02       Impact factor: 4.379

7.  Biomarkers for the diagnosis and post-Kasai portoenterostomy prognosis of biliary atresia: a systematic review and meta-analysis.

Authors:  Lin He; Dennis Kai Ming Ip; Greta Tam; Vincent Chi Hang Lui; Paul Kwong Hang Tam; Patrick Ho Yu Chung
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

8.  Re-evaluation of Laparoscopic Hepatic Subcapsular Spider-Like Telangiectasis Sign: A Highly Accurate Method to Diagnose Biliary Atresia in Infants.

Authors:  Yibo Li; Liying Rong; Jingfeng Tang; Huizhong Niu; Zhu Jin; Yun Zhou; Guoqing Cao; Xi Zhang; Shuiqing Chi; Shaotao Tang
Journal:  Front Pediatr       Date:  2022-04-25       Impact factor: 3.418

9.  Serum Proteomics Uncovers Biomarkers of Clinical Portal Hypertension in Children With Biliary Atresia.

Authors:  Julie Osborn; Reena Mourya; Unmesha Thanekar; Weizhe Su; Lin Fei; Pranavkumar Shivakumar; Jorge A Bezerra
Journal:  Hepatol Commun       Date:  2021-12-27

Review 10.  Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases.

Authors:  Eline Geervliet; Ruchi Bansal
Journal:  Cells       Date:  2020-05-13       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.